Get started
Author

Ryutaro Shimazaki

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism
2018 · Masafumi Fukagawa, Ryutaro Shimazaki, et al. · Kidney International · 101
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
2015 · Yoshimasa Kosaka, Yoshiaki Rai, et al. · Supportive Care in Cancer · 100
PDF
Nrf2 activator for the treatment of kidney diseases
2018 · Kengo Yamawaki, Hironori Kanda, et al. · Toxicology and Applied Pharmacology · 62
PDF
Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate
2016 · Kunihiro Matsushita, Jingsha Chen, et al. · Kidney International · 62
Neutralizing Antibody-Independent SARS-CoV-2 Control Correlated with Intranasal Vaccine-Induced CD8 + T-Cell Responses
2021 · Hiroshi Ishii, Takushi Nomura, et al. · Cell Reports Medicine · 57
PDF
Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial
2015 · Norikazu Masuda, Yutaka Tokuda, et al. · Supportive Care in Cancer · 45
PDF
A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE (R) chemotherapy for malignant lymphoma
2016 · Kohmei Kubo, Yasuhiko Miyazaki, et al. · British Journal of Haematology · 43
PDF
Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism
2016 · Yasuhiro Takeuchi, Shunsuke Takahashi, et al. · Journal of Bone and Mineral Metabolism · 39
An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome
2018 · the Antithrombin Gamma Study Group, Shigeatsu Endo, et al. · Journal of Intensive Care · 36
PDF
Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
2018 · Tadao Akizawa, Ryutaro Shimazaki, et al. · PLoS ONE · 30
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
2019 · Keitaro Yokoyama, Ryutaro Shimazaki, et al. · Scientific Reports · 27
PDF
Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
2019 · Kazuhiko Tsuruya, Ryutaro Shimazaki, et al. · Clinical and Experimental Nephrology · 20
PDF
Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
2018 · Evocalcet Study Group, Tadao Akizawa, et al. · Clinical Drug Investigation · 20
PDF
High Hemoglobin Levels Maintained by an Erythropoiesis‐Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment
2015 · Yoshiharu Tsubakihara, Tadao Akizawa, et al. · Therapeutic Apheresis and Dialysis · 19
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
2018 · Evocalcet Study Group, Takashi Shigematsu, et al. · Clinical and Experimental Nephrology · 17
PDF
Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
2018 · Takashi Shigematsu, Ryutaro Shimazaki, et al. · Clinical Pharmacology Advances and Applications · 16
PDF
First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia
2018 · Hae Il Cheong, Han‐Wook Yoo, et al. · JBMR Plus · 15
PDF
A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes
2015 · Jun Ho Jang, Hironori Harada, et al. · International Journal of Hematology · 15
A mouse circadian proteome atlas
2026 · Yuta Otobe, Norie Deki-Arima, et al. · Molecular Cell · 14
Assessment of CYP ‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans
2018 · Kazuya Narushima, Hiroshi Maeda, et al. · Clinical and Translational Science · 14
PDF
Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension
2017 · Takashi Kadowaki, Satsuki Muto, et al. · Expert Opinion on Pharmacotherapy · 7
PDF
Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
2019 · Evocalcet Study Group, Tadao Akizawa, et al. · Clinical Drug Investigation · 2
PDF
Development of intranasal Sendai virus vector-based vaccine against COVID-19
2021 · Ryutaro SHIMAZAKI, Kohji KUSANO · Translational and Regulatory Sciences · 1
Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
2019 · Evocalcet Study Group, Kazuhiko Tsuruya, et al. · Clinical and Experimental Nephrology
PDF
Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension
2017 · Kadowaki, Takashi, Muto, Satsuki, et al. · Figshare
Works count: 26
Citation count: 762
H-index: 16
I10-index: 20
Year
Topic
Type